ALX Oncology (NASDAQ:ALXO) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note released on Tuesday,Benzinga reports.

Several other research analysts also recently commented on ALXO. Lifesci Capital downgraded shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Stifel Nicolaus restated a “hold” rating and issued a $3.00 price target (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. UBS Group decreased their price target on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

ALX Oncology Stock Performance

Shares of ALXO opened at $1.34 on Tuesday. The company has a market capitalization of $70.58 million, a PE ratio of -0.50 and a beta of 1.03. ALX Oncology has a one year low of $1.34 and a one year high of $17.83. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.39 and a quick ratio of 4.39. The company’s fifty day moving average price is $1.75 and its 200 day moving average price is $5.85.

Institutional Trading of ALX Oncology

Several institutional investors have recently made changes to their positions in the business. Redmile Group LLC boosted its position in shares of ALX Oncology by 18.2% during the 1st quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock valued at $48,241,000 after acquiring an additional 667,245 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of ALX Oncology by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after acquiring an additional 64,055 shares in the last quarter. Marshall Wace LLP boosted its position in shares of ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after acquiring an additional 514,133 shares in the last quarter. Privium Fund Management B.V. boosted its position in shares of ALX Oncology by 28.2% during the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after acquiring an additional 112,093 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of ALX Oncology by 87.2% during the 2nd quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after acquiring an additional 204,100 shares in the last quarter. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.